Effect of spironolactone on cardiacsympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy
Shu Kasama, MD*,*,
Takuji Toyama, MD*,
Hisao Kumakura, MD ,
Yoshiaki Takayama, MD,
Shuichi Ichikawa, MD,
Tadashi Suzuki, MD* and
Masahiko Kurabayashi, MD*
* Second Department of Internal Medicine, Gunma University School of Medicine, MaebashiJapan
Kitakanto Cardiovascular Hospital, Gunma, Japan
View larger version (15K):
[in a new window]
|
Figure 1 Cardiac 123I-MIBG uptake was quantified as the H/M ratio 4 h after injection, using regions of interest positioned over the heart (H) and upper mediastinum (M).
|
|
View larger version (14K):
[in a new window]
|
Figure 2 Segmentation scheme used to quantitate regional 123I-MIBG uptake.
|
|
View larger version (18K):
[in a new window]
|
Figure 3 Changes in New York Heart Association (NYHA) functional class during treatment in the two groups.
|
|
View larger version (13K):
[in a new window]
|
Figure 4 Correlation between the changes in the 123I-MIBG scintigraphic findings and changes in left ventricular end-diastolic volume (LVEDV) after six months of spironolactone treatment in 15 patients with dilated cardiomyopathy. Delta LVEDV = LVEDV value after six months – pretreatment value of LVEDV; delta TDS = total defect score (TDS) value after six months – pretreatment value of TDS; delta H/M ratio = H/M ratio after six months – pretreatment value of H/M ratio; delta WR = washout rate (WR) value after six months – pretreatment value of WR.
|
|
|
